930 Winter Street
Suite M-500
Waltham, MA 02451
United States
617 443 2400
https://aerovatetx.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 51
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Timothy P. Noyes M.B.A. | CEO & Director | 936,9k | S.O. | 1962 |
Mr. George A. Eldridge | CFO & Treasurer | 658,6k | S.O. | 1963 |
Mr. Timothy J. Pigot | Chief Commercial Officer | 584,6k | S.O. | 1971 |
Dr. Benjamin T. Dake Ph.D. | Founder, President, COO & Secretary | 435,5k | S.O. | 1976 |
Dr. Marinus Verwijs Ph.D. | Chief Technical Officer | 439,88k | S.O. | 1976 |
Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S | Chief Scientific Officer | 372,33k | S.O. | 1960 |
Mr. Hunter Gillies M.D. | Chief Medical Officer | 512,74k | S.O. | 1966 |
Ms. Donna Dea | Head of Regulatory Affairs | S.O. | S.O. | S.O. |
Ms. Susan Fischer | Executive Vice President of Development Operations | S.O. | S.O. | S.O. |
Mr. Stephen K. Yu | Senior Vice President of Quality | S.O. | S.O. | S.O. |
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
L’ISS Governance QualityScore de Aerovate Therapeutics, Inc. en date du 1 mai 2024 est 8. Les scores principaux sont Audit : 8; Société : 8; Droits des actionnaires : 8; Compensation : 9.